Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses a person successfully using a combination of Minoxidil, finasteride, and other treatments for hair loss, resulting in significantly improved hair. Despite some criticism, many admire his dedication to health and anti-aging research.

The conversation discusses updates on hair loss treatments, specifically GT20029, PP405, and a rumored injectable peptide from UT. GT20029 is seen as a promising treatment expected within 5-7 years.

Hopeful treatments for hair loss, including Verteporfin, Androgen Receptor Degradation, and SCUBE3. These treatments offer potential solutions to slow or stop the effects of androgens on the scalp.

A user developed AI software to simulate hair transplants on photos, helping people visualize potential results. The tool offers photo-realistic renderings but advises caution regarding exact outcomes due to various factors.

KX-826 shows promising results for hair growth with fewer side effects, offering an alternative to finasteride and minoxidil. Users discuss combining it with minoxidil, dermarolling, and Nizoral for improved results.

Peptides like GHK-Cu, BPC-157, and TB-500 have significantly reduced hair loss, with GHK-Cu being particularly effective. The discussion also covers the high cost of these peptides and explores more affordable purchasing options.

KX-826 shows promise for hair maintenance at higher doses with minimal side effects, despite failing Phase III trials. The user believes it is more effective than Minoxidil, Finasteride, and RU58841.

A user discusses their hair loss journey, starting with 5% minoxidil and nizoral, and now using DualGen-15 Plus with 15% minoxidil and 0.1% finasteride. They also use biotin, pumpkin seed oil, Pura D'or Professional shampoo, and derma rolling, noting some shedding and side effects.

DHT causes hair loss by driving cells into senescence, and a polyphenol in black chokeberry may reverse this. A product using this theory is being considered for use alongside finasteride, minoxidil, and microneedling.

KX-826 is discussed as a hair loss treatment, with comparisons to finasteride. It is noted to be more expensive, harder to source, and generally used for stabilization rather than growth.

The conversation is about the anticipated release timeline for a hair loss treatment called GT20029. It may be available on the gray market in 1-2 years and officially in 3-4 years after completing clinical trials.

Han Bio plans to start Phase 1 clinical trials for a hair growth treatment in 2027 after successful results in mice. Many users express skepticism about the effectiveness of treatments that work on mice but not on humans, and discuss existing treatments like finasteride and minoxidil.

A user created a tracker for hair loss treatments in clinical development, including compounds like Dermaliq, RU58841, and Pyrilutamide. The tracker updates with new information and allows filtering by conditions like androgenetic alopecia (AGA) and alopecia areata (AA).

The conversation is about hair loss treatments, specifically discussing the use of dutasteride, minoxidil, and the potential benefits of a DNA test and PRP therapy. Opinions vary, with some users skeptical about the DNA test and PRP, suggesting sticking with current treatments.

The conversation discusses the effectiveness of pyrithione zinc and GT20029 for hair loss. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

The user is experiencing irritation from using PG with RU58841 and is seeking alternative solutions like K&B in the UK. They report redness, itchiness, and flaky skin from the current treatment.

The conversation discusses finding a source for RU58841 in Australia. Users suggest that while RU58841 is effective, it may harm the scalp, and recommend trying koshine's kx as a safer alternative.

A user shared progress pictures of their FUT hair transplant in Korea, showing results one year post-op. The conversation highlights the density of the hair, the quality of Korean hair treatments, and mentions treatments like Minoxidil, finasteride, and Dutasteride.

The conversation is about a user offering an unopened bottle of KX-826 (0.5%) for hair loss treatment, stating it works well for them. They are selling it at cost without seeking profit.

Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.

Hair loss discussion includes treatments like hinoki tree oil and procyanidin b2. Experiences and effectiveness of these treatments are shared.

A new hair loss treatment involving Keratin Microsphere Gel is discussed, with skepticism and jokes about its effectiveness and comparisons to other treatments. Users are doubtful and make light of the situation, referencing past disappointments and the study's focus on mice.

A dermatologist checked for hereditary hair loss using blood tests and plans to perform a trichogram. The user had slightly low Vitamin D3 levels, and the trichogram may help confirm androgenetic alopecia.

The conversation discusses a personalized hair loss treatment plan based on DNA test results, recommending Minoxidil, Dutasteride, 17-alpha Estradiol, Cetirizine, and PRP sessions. The test identifies a high risk of hair loss due to DHT but a good response to Minoxidil, suggesting a tailored approach to treatment.

Tressless GPT is now free and accessible for hair loss advice. Treatments discussed include Minoxidil, finasteride, RU58841, dutasteride mesotherapy, topical melatonin, microneedling, and rapamycin.

New treatments for AGA are emerging, including pyrilutumide, gt0029, scube3, kx-826, and pp405. Verteporfin is mentioned as a promising option.

The conversation discusses the potential effectiveness and future results of the hair loss treatment pp405, with questions about its impact on different hair loss stages and areas. There is anticipation for phase 3 trial results to provide more data, and hope that pp405 could enhance hair transplant outcomes.

The conversation is about the availability of gt20029 for hair loss treatment, indicating that it will not be available for purchase soon. No specific treatments were discussed.

PG solvent is considered superior to K&B solvent for RU58841 and Pyralutamide due to cost and effectiveness. The user questions why they should use K&B when PG offers more benefits.

The conversation discusses the delay in the release of a new hair loss treatment, Pyrilutamide, and speculates on potential safety concerns as a reason for the delay. It also mentions GT20029 as another future treatment option, with a release at least five years away, and touches on the avoidance of research chemicals due to uncertainty about their authenticity.